Product Name |
Code |
Species Reactivity |
Application |
Size |
---|---|---|---|---|
LEFTY2 Recombinant Monoclonal Antibody |
CSB-RA171603A0HU | Human | ELISA, WB | 100μl/50μl |
KLRG1 Recombinant Monoclonal Antibody |
CSB-RA233042A0HU | Human | ELISA, FC | 100μl/50μl |
CBX2 Recombinant Monoclonal Antibody |
CSB-RA632623A0HU | Human, Rat | ELISA, WB | 100μl/50μl |
SMAD4 Recombinant Monoclonal Antibody |
CSB-RA551397A0HU | Human | ELISA, WB | 100μl/50μl |
STK33 Recombinant Monoclonal Antibody |
CSB-RA207790A0HU | Human | ELISA, IHC | 100μl/50μl |
ITGA6 Recombinant Monoclonal Antibody |
CSB-RA172768A0HU | Human | ELISA, IF, FC | 100μl/50μl |
COPS3 Recombinant Monoclonal Antibody |
CSB-RA556985A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
RAB27A Recombinant Monoclonal Antibody |
CSB-RA285197A0HU | Human | ELISA, FC | 100μl/50μl |
CSN2 Recombinant Monoclonal Antibody |
CSB-RA959139A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
FIS1 Recombinant Monoclonal Antibody |
CSB-RA334524A0HU | Human | ELISA, WB, IHC | 100μl/50μl |
OS9 Recombinant Monoclonal Antibody |
CSB-RA959292A0HU | Human, Mouse | ELISA, WB, IHC | 100μl/50μl |
SENP1 Recombinant Monoclonal Antibody |
CSB-RA150103A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
BCAP31 Recombinant Monoclonal Antibody |
CSB-RA834263A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
HIF1AN Recombinant Monoclonal Antibody |
CSB-RA256295A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
CDX1 Recombinant Monoclonal Antibody |
CSB-RA987794A0HU | Human | ELISA, WB, IF Recommended dilution: WB:1:500-1:2000, IF:1:50-1:200 | 100μl/50μl |
PTX3 Recombinant Monoclonal Antibody |
CSB-RA984883A0HU | Human | ELISA, FC | 100μl/50μl |
NUF2 Recombinant Monoclonal Antibody |
CSB-RA248269A0HU | Human | ELISA, WB | 100μl/50μl |
RPS19 Recombinant Monoclonal Antibody |
CSB-RA940350A0HU | Human | ELISA, WB, FC | 100μl/50μl |
PSME1 Recombinant Monoclonal Antibody |
CSB-RA943230A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
USP14 Recombinant Monoclonal Antibody |
CSB-RA587609A0HU | Human | ELISA, WB, IF Recommended dilution: WB:1:500-1:2000, IF:1:50-1:200 | 100μl/50μl |
RAB25 Recombinant Monoclonal Antibody |
CSB-RA284745A0HU | Human | ELISA, IF | 100μl/50μl |
STAT4 Recombinant Monoclonal Antibody |
CSB-RA547973A0HU | Human | ELISA, IHC, IF | 100μl/50μl |
E2F4 Antibody |
CSB-RA179313A0HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
ACO1 Recombinant Monoclonal Antibody |
CSB-RA298469A0HU | Human | ELISA, WB, IF, FC | 100μl/50μl |
ALCAM Recombinant Monoclonal Antibody |
CSB-RA437652A0HU | Human, Mouse | ELISA, WB, IHC | 100μl/50μl |
PKN2 Recombinant Monoclonal Antibody |
CSB-RA921617A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
BMP4 Recombinant Monoclonal Antibody |
CSB-RA257673A0HU | Human | ELISA, WB, IF Recommended dilution: WB:1:500-1:2000, IF:1:50-1:200 | 100μl/50μl |
USP22 Recombinant Monoclonal Antibody |
CSB-RA784212A0HU | Human | ELISA, WB, IF, FC | 100μl/50μl |
KDM1B Recombinant Monoclonal Antibody |
CSB-RA958367A0HU | Human | ELISA, WB | 100μl/50μl |
PRDX3 Recombinant Monoclonal Antibody |
CSB-RA437344A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
ENTPD1 Recombinant Monoclonal Antibody |
CSB-RA568544A0HU | Human | ELISA, FC | 100μl/50μl |
MBD1 Recombinant Monoclonal Antibody |
CSB-RA794480A0HU | Human | ELISA, IF | 100μl/50μl |
OCLN Recombinant Monoclonal Antibody |
CSB-RA293053A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
HSP90AB1 Recombinant Monoclonal Antibody |
CSB-RA904894A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
YWHAB Recombinant Monoclonal Antibody |
CSB-RA616077A0HU | Human, Mouse, Rat | ELISA, WB, IF, FC | 100μl/50μl |
PRKAG1 Recombinant Monoclonal Antibody |
CSB-RA161743A0HU | Human | ELISA, IHC | 100μl/50μl |
STK3 Recombinant Monoclonal Antibody |
CSB-RA980100A0HU | Human | ELISA, WB | 100μl/50μl |
ITGAL Recombinant Monoclonal Antibody |
CSB-RA787996A0HU | Human | ELISA, WB, IF Recommended dilution: WB:1:500-1:2000, IF:1:50-1:200 | 100μl/50μl |
TFPI Recombinant Monoclonal Antibody |
CSB-RA023437MA01HU | Human, Rabbit | ELISA | 100μl/50μl |
SEMA4D Recombinant Monoclonal Antibody |
CSB-RA835707A2HU | Human, Mouse | ELISA, FC | 100μl/50μl |
PRLR Recombinant Monoclonal Antibody |
CSB-RA018727A0HU | Human, Mouse | ELISA | 100μl/50μl |
DSG3 Recombinant Monoclonal Antibody |
CSB-RA007205A0HU | Human, Mouse | ELISA | 100μl/50μl |
CXCR4 Recombinant Monoclonal Antibody |
CSB-RA006254MA01HU | Human | ELISA | 100μl/50μl |
CD74 Recombinant Monoclonal Antibody |
CSB-RA004956A1HU | Human | ELISA | 100μl/50μl |
MS4A1 Recombinant Monoclonal Antibody |
CSB-RA015007A1HU | Human | ELISA | 100μl/50μl |
C5AR1 Recombinant Monoclonal Antibody |
CSB-RA003996A0HU | Human | ELISA | 100μl/50μl |
ROR1 Recombinant Monoclonal Antibody |
CSB-RA020067A1HU | Human | ELISA, FC | 100μl/50μl |
NECTIN4 Recombinant Monoclonal Antibody |
CSB-RA822274A0HU | Human | ELISA | 100μl/50μl |
MAPT Recombinant Monoclonal Antibody |
CSB-RA013481A1HU | Mouse, Macaca mulatta | ELISA | 100μl/50μl |
GPRC5D Recombinant Monoclonal Antibody |
CSB-RA882153MA01HU | Human | ELISA | 100μl/50μl |
A stable and highly specific antibody plays an important role in obtaining real and repeatable experimental results. It is a big headache if the antibody used in the experiment does not work. And what's even worse is that you use the antibodies to repeat the same experiment but get inconsistent results.
It is estimated that the annual loss in research funding due to the use of antibodies without enough validation is about $ 800 million worldwide. At the same time, it has caused countless experimental failures, and a waste of precious samples and researchers'youth.
Nowadays, the antibody validations information provided by antibody manufacturers and academic articles is very helpful for you to select high-quality antibodies. However, there is still an inevitable problem: whether it is polyclonal antibodies extracted from animal serum or monoclonal antibodies produced by hybridomas, there are more or fewer differences between batches. And recombinant antibodies may finally solve this problem.
Recombinant antibodies refers to the application of molecular cloning and gene mutation technology to transform a gene coding sequence of an antibody to produce superior performance of antibodies, also known as genetically engineered antibodies. Comparing with monoclonal antibodies generated in vivo of living animals through hybridoma technology, recombinant antibodies are a type of monoclonal antibodies which are produced in vitro by using synthetic genes.
In recent years, the use of recombinant antibodies is becoming increasingly wider and deeper in both therapeutics and diagnostics. With significant advantages over conventional antibodies, recombinant antibodies become more and more favored. The most important point is that recombinant antibodies can maximize the humanization to solve the heterogeneity between different species.
Generally speaking, recombinant antibodies can be divided into three classes, including chimeric antibody, humanized antibody, fully humanized antibody and small molecular antibody.
Compared with traditional antibodies, recombinant antibodies have the advantages of being irresistible, which is one of the reasons for their gradually emerging. Here, we present the advantages one by one as follows:
Because recombinant antibodies have these unprecedented advantages, recombinant antibodies fulfill a large spectrum of functions spanning from research to diagnosis and treatment therapies for various diseases. Their specificity and low immunogenicity make them a great alternative to traditional forms of treatment, increasing the accuracy of targeting specific molecules and avoiding adverse side effects.
Additionally, for recombinant antibodies production, it follows principally similar workflow. Generally, it consists of five steps: the construction of antibody gene library, phage display, the separation of antibodies, the modification of the isolated antibodies, and the scaling up of the production of selected antibodies in the cell culture expression system.
Although the processes of recombinant antibodies production are same as workflow, we need to recognize that there are several obstacles to the production of recombinant antibodies, such as lower antibody production, and highly trained and experienced technicians. Due to the complexity and intensive high technology of recombinant antibody production, most scientists need to obtain them from outsourcing companies.
Read the article, The Overview of Recombinant Antibody, for more information.
S Antibody referenced in "A magneto-optical biochip for rapid assay based on the Cotton–Mouton effect of γ-Fe2O3@ Au core/shell nanoparticles", Journal of nanobiotechnology, 2021.
SARS-CoV-2 Spike RBD Nanobody referenced in "Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2", Bioorganic & Medicinal Chemistry, 2021.
HIF1A Antibody, CASP3 Antibody referenced in "PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia", Cancer cell international, 2021.
Phospho-ERN1 (S724) Antibody referenced in "The ER stress sensor inositol-requiring enzyme 1α in Kupffer cells promotes hepatic ischemia-reperfusion injury", Journal of Biological Chemistry, 2021.
CDK4 Antibody and CDK6 Antibody referenced in "Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells Via Forkhead Box M1 Suppression", Journal of Cancer, 2021.
BIRC5 Antibody referenced in "LTBP4 Inhibits the Proliferation and Metastasis in Melanoma by Activating Hippo-YAP Signaling", Research Square, 2020.